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Abstract
Purpose To identify sources of exposure variability for
the tumor growth inhibitor 17-dimethylaminoethylamino-
17-demethoxygeldanamycin (17-DMAG) using a popula-
tion pharmacokinetic analysis.
Methods A total 67 solid tumor patients at 2 centers were
given 1 h infusions of 17-DMAG either as a single dose,
daily for 3 days, or daily for 5 days. Blood samples were
extensively collected and 17-DMAG plasma concentra-
tions were measured by liquid chromatography/mass
spectrometry. Population pharmacokinetic analysis of the
17-DMAG plasma concentration with time was performed
using nonlinear mixed effect modeling to evaluate the
effects of covariates, inter-individual variability, and
between-occasion variability on model parameters using a
stepwise forward addition then backward elimination
modeling approach. The inter-individual exposure vari-
ability and the effects of between-occasion variability on
exposure were assessed by simulating the 95 % prediction
interval of the AUC per dose, AUC0–24 h, using the ﬁnal
model and a model with no between-occasion variability,
respectively, subject to the ﬁve day 17-DMAG infusion
protocol with administrations of the median observed dose.
Results A 3-compartment model with ﬁrst order elimi-
nation (ADVAN11, TRANS4) and a proportional resid-
ual error, exponentiated inter-individual variability and
between occasion variability on Q2 and V1 best descri-
bed the 17-DMAG concentration data. No covariates
were statistically signiﬁcant. The simulated 95% predic-
tion interval of the AUC0–24 h for the median dose of
36 mg/m
2 was 1,059–9,007 mg/L h and the simulated
95 % prediction interval of the AUC0–24 h considering
the impact of between-occasion variability alone was
2,910–4,077 mg/L h.
Conclusions Population pharmacokinetic analysis of
17-DMAG found no signiﬁcant covariate effects and con-
siderable inter-individual variability; this implies a wide
range of exposures in the population and which may affect
treatment outcome. Patients treated with 17-DMAG may
require therapeutic drug monitoring which could help
achieve more uniform exposure leading to safer and more
effective therapy.
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Introduction
The compound 17-dimethylaminoethylamino-17-deme-
thoxygeldanamycin (17-DMAG) is a potential chemother-
apeutic treatment for solid tumors due to its ability to
degrade oncoproteins by inhibiting heat shock protein-90
[1–5], but its population pharmacokinetic characteristics
have yet to be evaluated. An analog of 17-DMAG,
17-(allylamino)-17-demethoxygeldanamycin (17AAG),
was the ﬁrst clinically evaluated heat shock protein 90
inhibitor [6]. However, 17-DMAG has more pharmaco-
logically desirable pharmacokinetic (PK) and pharmaco-
dynamic (PD) proﬁles because of its reduced metabolic
liability, lower plasma protein binding, increased water
solubility, higher oral bioavailability, reduced hepatotox-
icity and superior antitumor activity compared with
17AAG [5, 7–9]. Preclinical data suggest that, although
both 17-DMAG and 17-AAG are excreted primarily
through the hepatobiliary system, large differences exist
between them in their extent of plasma binding and
metabolism [10].
Phase I data indicate that the PK of 17-DMAG is linear,
withboththeareaunderthe17-DMAGconcentrationversus
time curve and the maximum concentration increasing pro-
portionally with dose escalation [8]. However, high inter-
individual variability in exposure to 17-DMAG despite
adjustment of dose to body surface area is a prominent
challenge;thecoefﬁcientofvariationin17-DMAGexposure
can exceed 70 % [11, 12]. A previous 17-DMAG PK model
of concentration versus time data [8] employed a noncom-
partmental method that did not explicitly evaluate within
individual variability between occasions and is of limited
utility in determining inter-individual variability in drug
exposure [13]. The goal of this study was to characterize the
population pharmacokinetics of 17-DMAG, and to further
explain the nature of the variability in its exposure.
Patients and methods
Study setting and participants
The study was conducted at the University of Pittsburgh
Cancer Institute (PCI) and Memorial Sloan Kettering
Cancer Center (MSKCC). The study protocol was
approved by the Institution Review Board of both PCI and
MSKCC. All patients gave written, informed consent prior
to entering the study.
The study was a phase II assessment of 17-DMAG on
patients with a histologically conﬁrmed advanced solid
tumor not curable by standard therapies. Patients were
excluded if they had abnormal liver function (i.e. liver
transaminases ALT or AST higher than 1.5 of the upper
limit of normal); abnormal renal function (i.e. blood urea
nitrogen and creatinine outside the normal range); or
Eastern Cooperative Oncology Group performance status
[2. Patients with the following cardiac conditions were
excluded because of a prior unconﬁrmed link of 17-AAG
with cardiac toxicity [14]: personal history of long QT
syndrome; New York class III or IV heart failure; con-
current use of drugs that prolong QTC; personal history of
arrhythmia; QTC C 450 ms in males or C470 ms in
females; poorly controlled angina; uncontrolled dysrhyth-
mias requiring antiarrhythmic drug(s); ejection fraction
B40 % by multiple gated study; history of serious ven-
tricular arrhythmia (ventricular tachycardia or ventricular
ﬁbrillation, three or more consecutive premature ventricu-
lar contractions); history of cardiac radiation; or left bundle
branch block. Patients with symptomatic pulmonary dis-
ease requiring medications or home oxygen were also
excluded.
Drug administration and pharmacokinetic assessment
The Division of Cancer Treatment and Diagnosis (Rock-
ville, MD) supplied 17-DMAG under a cooperative
research and development agreement. Sterile, 10 or 50 mg
vials of lyophilized 17-DMAG were reconstituted with
citrate buffer and mannitol to yield a 5 mg/mL solution.
This was further diluted in normal (0.9 %) saline to con-
centrations between 0.1 and 1 mg/mL and infused intra-
venously (IV) over 1 h. Antiemetic therapy with oral or
intravenous metoclopramide or prochlorperazine was
administered prior to drug administration to prevent nausea
and vomiting.
Patients at PCI were randomly assigned to one of two
schedules, A or B, and doses were adjusted between
patients. Schedule A patients received a starting dose of
1.5 mg/m
2 IV daily for 5 days while patients in schedule B
received a starting dose of 2.5 mg/m
2 IV daily for 3 days.
Initial doses were doubled using an accelerated titration
schema. In this schema, doses were doubled after one or
two patients were accrued per dose level and continued
until toxicity higher than grade 2 was observed or a max-
imum tolerated dose was reached. After the dosage dou-
bling schema was discontinued due to toxicity, the
remaining patients were assigned to dose levels that
increased in approximately 35 % increments until the
maximum tolerated dose was reached. At MSKCC, a range
of possible doses was pre-speciﬁed and each patient
received one single infusion.
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123PCI patients had serial blood samples collected at
baseline, 0.5, 0.92, 1.08, 1.17, 1.25, 1.5, 2.0, 3.0, 5.0, 13.0,
17.0, and 25.0 h after the start of the baseline infusion.
Blood samples were also collected prior to the start of the
second (25.0 h) and third (49.0 h) infusions. If the patient
received 3 doses (schedule B), additional samples were
collected at 49.5, 49.92, 50.08, 50.17, 50.25, 51.0, 52.0,
and 53.0 h. If the patient received 5 doses (Schedule A),
additional samples were collected at the start of the fourth
(73.0 h) and ﬁfth (97 h) infusions and at 97.5, 97.92, 98.08,
98.17, 98.25, 98.5, 99.0, 100.0, 102.0 h. MSKCC patients
received a single infusion and serial blood samples were
collected at 0, 0.5, 0.93, 1.5, 2.0, 4.0, 6.0, 24.0, and 48 h
after the start of the infusion. The serial blood samples
(5 mL) were collected into heparinized tubes.
Blood samples were centrifuged at 1,0009g for 10 min
and the supernatant (plasma) was stored at -70 C. Con-
centrations of 17-DMAG in the blood were measured using
a liquid chromatography/mass spectrometry assay. This
assay was developed and validated at the University of
Pittsburgh [15].
Population pharmacokinetic modeling approach
The concentration sampling and dosage history data were
combined across the PCI and MSKCC study groups for
population PK analysis. Population PK analysis of the
17-DMAG plasma concentration with time was performed
using the nonlinear mixed effect modeling software pro-
gram NONMEM, Version 5.1.1 (GloboMax LLC, Elliot
City, Maryland) and the ﬁnal model was conﬁrmed by re-
running the ﬁnal model in NONMEM, Version 7.1.2
Base model structure
The initial modeling focused on selecting a base model
structure without incorporating any covariates. Linear
2- (ADVAN3, TRANS4) and 3-compartment (ADVAN11,
TRANS4) PK models with ﬁrst order elimination were
evaluated. Inter-individual variability (IIV) and between-
occasion variability (BOV) random effects were included
in the base model and assumed to be log-normally dis-
tributed. For example, the value of model parameter P after
the kth dose administered to the ith individual, Pi,k,i s
Pi;k ¼ PTV   e
ðn
ðPÞ
i þj
ðPÞ
i;k Þ
where PTV is the typical value of the model parameter, gi
(P)
is the inter-individual variability, and ji,k
(P) is the between-
occasion variability.
The BOV was tested on each PK parameter separately
by a likelihood ratio test using the objective function values
(OFVs) output of NONMEM. The OFV is equal to -29
Log-likelihood (-2LL), and the difference in OFV
between models is approximately Chi-square distributed.
Each BOV was incorporated one at a time on each
parameter in a stepwise forward and then backward elim-
ination fashion. If the OFV did not decrease by at least 3.84
points (p\0.05, 1degree of freedom) after the addition or
increase by at least 6.63 points (p\0.01, 1 degree of
freedom) after the removal, BOV on that parameter was
not considered signiﬁcant and removed from further con-
sideration in the model. Model structural selection was
guided by objective function as well as the Akaike Infor-
mation Criterion (AIC).
Additive (yi;j ¼ ^ y þ ei;j), proportional (yi;j ¼ ^ yþ
ð1 þ ei;jÞ), and combined error (yi;j ¼ ^ yi;jð1 þ ei;jÞþe0
i;j )
residual error structures were tested, where yi,j is the jth
observedDMAGconcentrationintheithindividual,^ yi;j isthe
corresponding model prediction, and ei,j (and ei,j
0
) is the
residual error which is assumed to be normally distributed
with a mean of 0 and a variance of r
2 (and r
02).
Covariate assessment
Differences in patients’ demographic characteristics may
explainsomeofthevariabilityinthePKparameterestimates.
Inthis study,thecontinuouscovariates age,albumin, alanine
aminotransferase, aspartate transaminase, bilirubin, blood
urea nitrogen, body surface area, creatinine, and weight and
the discrete covariate sex were tested. The effect of contin-
uous covariates on the typical value of a parameter was
modeled using additive, proportional, emax and exponenti-
ated forms. An example of the implementation of a typical
continuous covariate (centered, exponentiated) is
PTV ¼ h1 exp h2
Cov
medianðCovÞ

where h1 and h2 are estimated ﬁxed effect parameters and
Cov is the subject-speciﬁc value of the covariate.
Categorical (binary) values were assigned to each
discrete variable (such as sex), and their effect on PK
parameters were modeled as
PTV ¼ h1 if Cov ¼ 1
PTV ¼ h2 if Cov ¼ 2
For the ﬁnal model, each covariate was tested individually
usingthestepwiseforwardadditionthenbackwardelimination
method using the model discrimination criteria previously
described for BOV evaluation. In addition, diagnostic plots
of observed concentrations versus population predictions,
observed concentrations versus individual predictions,
weighted residuals versus population predictions, and
weighted residuals with time were inspected for systematic
deviation.
Cancer Chemother Pharmacol (2012) 70:201–205 203
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Patient characteristics
A total of 67 subjects (48 PCI and 19 MSKCC) participated
in the study (Table 1). The subjects received a median
infusion dose of 36 mg/m
2 (range of 2.2–413 mg/m
2) and
contributed a total of 1,148 17-DMAG plasma concentra-
tion measurements (1,000 PCI and 148 MSKCC). No
subjects or 17-DMAG concentrations were excluded. The
majority of subjects were male (42 vs. 25) and had a
median age of 63 years and a median weight of 80.3 kg.
Population pharmacokinetic modeling
A 3-compartment model with ﬁrst order elimination
(ADVAN11, TRANS4) and a proportional residual error
best described the 17-DMAG concentration data in this
population. Between-occasion variability was signiﬁcant
only on Q2 and V1. None of the covariates showed a
signiﬁcant relationship with the parameter values.
All ﬁxed and random effects were well determined in
the ﬁnal model (Table 2). The population average for the
clearance and inter-compartmental clearances were 8.4,
85.1, and 11.6 L/h, respectively. Volumes for the three
compartments were 27.4, 66.4 and 142 L, respectively. The
inter-individual variability for CL, Q3, V1, V2 and V3
were 53.8, 75.8, 33.0, 50.7, and 67.5 %, respectively. The
between-occasion variability on Q2 and V1 were 32.6 and
59.7 %, respectively. A proportional error model was used
and the proportional residual error was 16.1 %. Diagnostic
plots are available in the supplemental material.
Effects of inter-occasion variability and between-
occasion variability on 17-DMAG exposure
Because of the absence of covariate effects on the model
parameters and the wide inter-individual variability in this
population PK analysis, the population exposure to
17-DMAG was quantiﬁed in a post hoc Monte Carlo
simulation. The ﬁnal model was used to simulate the 95%
prediction interval for the area under the 17-DMAG con-
centration time curve per dose, AUC0–24 h, for the ﬁve dose
infusion protocol with 36 mg/m
2 doses. The simulated
95 % prediction interval of the AUC0–24 h with both IIV
and BOV was 1,059–9,007 mg/L h.
Because of the wide range of exposures due to IIV, a
second post hoc analysis was performed to simulate the
variability in exposure due to BOV. Typical model
parameters (i.e. no IIV) were used to simulate the 95%
prediction interval of the AUC0–14 h for the ﬁve dose
infusion protocol with 36 mg/m
2 doses. The simulated
95% prediction interval of the AUC0–24 h with BOV only
was 2,910–4,077 mg/L h.
Discussion
In this study, we implemented the ﬁrst population PK
analysis to identify, measure, and characterize the potential
Table 1 Patient characteristics
Characteristics N (%) Median (Range)
Number of patients 67
Pittsburgh Cancer Institute 48 (72 %)
Memorial Sloan-Kettering 19 (28 %)
Number of observations 1,148 21 (7–25)
Pittsburgh 1,000
(87 %)
23 (10–25)
Memorial Sloan-Kettering 148 (13 %) 8 (7–9)
DMAG dose, lg 36,000
(2,200–413,000)
DMAG concentration, lg/mL 203.5 (1–5,542)
Age, years
a 63 (28–82)
Sex
Male 42 (63 %)
Female 25 (37 %)
Weight, kg
a 80.3 (48.2–136.5)
Albumin, g/dL
b 3.8 (2.6–5.1)
Alanine aminotransferase,
units/L
22 (10–106)
Aspartate transaminase,
units/L
25 (12–75)
Bilirubin, mg/dL 0.5 (0.1–3.0)
Blood urea nitrogen, mg/dL
c 15 (5–70)
Body surface area, m
2 1.9 (1.5–2.6)
Creatinine, mg/dL 1.0 (0.6–1.8)
a One patient is missing data for age, weight, albumin, alanine ami-
notransferase, aspartate transaminase, bilirubin, blood urea nitrogen,
and creatinine
b Albumin measurements were missing for 6 patients
c Blood urea nitrogen measurements were missing for 2 patients
Table 2 Parameter values for ﬁnal model
Parameter Population
estimate
(%SE)
Inter-individual
variability
(%SE)
Between-occasion
variability
(%SE)
CL 8.4 (11.2) 53.8 % (22.9) –
Q2 85.1 (9.6) – 32.6 % (37.2)
Q3 11.6 (13.1) 75.8 % (32.0) –
V1 27.4 (11.7) 33.0 % (111.9) 59.7 % (31.2)
V2 66.4 (10.1) 50.7 % (23.7) –
V3 142 (13.5) 67.5 % (37.3) –
Proportional
error
16.1 % (2.7) – –
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123sources of variability in 17-DMAG concentrations using
data from patients with advanced solid tumors. These
analyses suggest that 17-DMAG disposition is best
described using a three-compartment, linear model. There
were no statistically signiﬁcant effects of covariates on
parameters in the model. The wide inter-individual vari-
ability in this model leads to considerable variation in
exposure to 17-DMAG between individuals which is con-
sistent with previous studies [11, 12]. But, based on our
results, we cannot comment on whether or not this ﬂuctu-
ation contributed to the lack of PK/PD correlation in the
previous studies [8, 12]. The challenge of substantial var-
iability in its pharmacokinetic parameters hinders the
implementation of 17-DMAG and such wide variations in
exposure may reduce efﬁcacy and precipitate toxicity in
under-, and over-exposed patients respectively. In addition,
the BOV of 32.6 % in inter-compartmental clearance (Q2)
and 59.7 % variability in the volume of the central com-
partment did not have a considerable impact on the dose to
dose exposure within a given individual. In light of the
considerable IIV, this result suggests a role for therapeutic
drug monitoring to characterize individual PK character-
istics after single dose of 17-DMAG.
The study included only patients with adequate hepatic,
hematological, and renal function to ensure safety and
adequate drug metabolizing capability. As such, the effects
of extreme derangements in hepatic, hematological, and
renal function on the pharmacokinetics of 17-DMAG are
unknown. In order to effectively capture covariate rela-
tionships such as hepatic and renal function on 17-DMAG
pharmacokinetics, a wider range of values for the covari-
ates would be necessary. Our strict inclusion/exclusion
criteria precluded this. Despite controlling for a relatively
homogenous study population, our analysis still contain
signiﬁcant random IIV. Therefore, this model has limited
utility for dosage targeting prior to the ﬁrst dose, as
evidenced by the individual predictions (Supplemental
Figure 1). However, once a plasma concentration sample is
measured, the dosage can be much more precisely tailored
at the individual level.
In addition, the model could provide the basis for sim-
ulation of future 17-DMAG clinical trials, the selection of
optimal sampling points to enhance the capture of inter-
individual variability, and the possibility of covariate
effects that were undetected in these analyses.
Strengths of this study include multiple dosing, frequent
and multiple sampling, appropriate target population
(cancer patients), and data from multiple centers to
strengthen the conclusions of these analyses.
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